Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation

Area of Science:

• Medicinal Chemistry
• Chemical Biology
• Drug Discovery

Background:

• Covalent drugs, including aspirin and penicillin, are widely used but carry risks of toxicity due to their reactivity.
• Historically, the potential drawbacks of covalent binding led to its deprioritization in drug discovery.
• Recent approvals of covalent inhibitors for cancer have reignited interest in selective covalent targeting.

Purpose of the Study:

• To review the history and emerging developments in selective covalent targeting from a chemical biology perspective.
• To discuss strategies for validating irreversible covalent ligands and expanding target scope.
• To explore the discovery of novel covalent ligands and warheads.

Main Methods:

• Literature review focusing on chemical biology principles.
• Analysis of historical trends in covalent drug development.
• Examination of recent advancements in ligand and warhead discovery.

Main Results:

• Covalent binding offers advantages in drug potency, selectivity, and duration.
• Despite historical concerns, selective covalent inhibitors are proving effective, particularly in oncology.
• Significant progress has been made in validating covalent ligands and identifying new targets.

Conclusions:

• Selective covalent targeting is a rapidly advancing field with renewed potential in drug discovery.
• Overcoming limitations and capitalizing on emerging opportunities are key for future development.
• Further research into novel warheads and target engagement is warranted.